Novo Nordisk A/S (NVO) — closed signal from May 25, 2026
Target reached Published before the outcome was known, scored automatically when the window closed on August 23, 2026.
Predicted vs. what happened
NVO price · publication thesis → realized outcomesplit-adjusted
$42.41 – $43.87Entry zone — fair-value band
$44.39Published — price the day we called it
$46.90Target — the price the thesis aimed for
$51.46Peak — highest point inside the window, not a realized return
$46.74Window close — end-of-window price, context only
What happened
Target reached
Reached its target in 31 days.
Peak price
$51.46
peak on July 29, 2026 — not a realized returnPeak gain
+15.9%
peak, from the publication priceWindow close
$46.74
end-of-window price, context onlyDays to target
31
Window
May 25, 2026 – August 23, 2026
The thesis — published May 25, 2026
Predicted growth
+7%
over the measurement windowTarget price
$46.90
the price the thesis aimed forEntry zone
$42.41 – $43.87
the fair-value band we waited forPrice at publication
$44.39
published May 25, 2026Confidence
71%
how strongly the data lined upTimeframe
Short-term (0–3 months)
Novo Nordisk offers steady exposure to healthcare because its diabetes and obesity treatments keep selling. The stock looks fairly valued and tends not to swing with the market, which makes gains likely to be modest. Recent competitive drug news and a weak earnings report mean the near-term outlook is cautious rather than fast growth.
Primary drivers
- Strong ongoing demand for diabetes and obesity medicines
- Reasonable valuation makes the stock a defensive option
- Lower sensitivity to market swings reduces volatility in portfolios
- Recent rival drug news limits near-term upside potential
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Lyra
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.